|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Subcutaneous versus in- travenous administration of bortezomib in patients with relapsed muhiple mycloma : A randomised, phase 3, non - inferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 2 | Updated survival analysis of a randomized phase III study of subcutaneous versus intrave- nous bortezomib in patients with relapsed multiple myeloma 显示文摘 | Arnulf B Pylypenko H Grosicki S | 2012 | Haematologica2012，7，12： | 1 |
| 3 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 4 | Subcutane ous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised,phase 3,non-inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，： | 1 |
| 5 | Updated survival analysis of a randomized phase Ⅲ study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma 显示文摘 | Arnulf B Pylypenko H Grosicki S | 2012 | Haematological2012，97，12： | 1 |
| 6 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised,phase 3,non-inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 7 | Subcutaneous versus in- travenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY - 3021 study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2015 | Haematologica2015，100，5： | 1 |
| 8 | Subcutaneous versus intra-venous administration of bortezomibin patients with relapsed multiplemyeloma : a randomised,phase 3,non-inferiority study显示文摘 | Moreau P Pylypenko H GrosickiS | 2011 | Lancet On-col2011，12，5： | 1 |
| 9 | Subcutaneouswith relapsed multiple myeloma : a randomised, phase 3,non-inferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 10 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 11 | Subcutaneous versus intravenous administration ofhortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 12 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomized,phase 3,non-inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，： | 1 |
| 13 | Subcutaneous versus in- travenous administration of bortezomib in patients with relapsed multiple myeloma : A randomized, phased 3 non - inferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 14 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised,phase 3, non-inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oncol2011，12，5： | 1 |
| 15 | Updated survival analysis of a randomized phase 111 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma显示文摘 | Arnulf B Pylypenko H Grosicki S | 2012 | Haematological2012，97，12： | 1 |
| 16 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study显示文摘 | MOREAU P PYLYPENKO H GROSICKI S | 2011 | The Lancet Oncology2011，12，5： | 1 |
| 17 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non- inferiority study显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet oncol2011，12，5： | 1 |
| 18 | Subcutaneous versus in- travenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, noninferiority study 显示文摘 | Moreau P Pylypenko H Grosicki S | 2011 | Lancet Oneol2011，12，： | 1 |
| 19 | Subcutaneous versus intravenous ad- ministration of boaezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non- inferiority study 显示文摘 | Moreau P Pylypenko H | 2011 | Lancet2011，12，： | 1 |
| 20 | Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY -3021 study显示文摘 | Moreau P Pylypenko H Grosicki S | 2015 | Haematologica2015，100，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员